Endoscopic therapy using a self-expandable metallic stent with an anti-migration system for postorthotopic liver transplantation anastomotic biliary stricture

Table 1 Demographics of patients and baseline characteristics

Overall patient characteristics	Results
No. of patients, n	14
Gender, female sex, n (%)	7 (50)
Age (yr), mean (range)	56 (28-76)
Cause of liver transplant: n
HBV	2
HBV + HCV	1
Alcohol	3
Cryptogenic	2
NASH	1
Autoimmune hepatitis	2
Primary biliary cirrhosis	1
Familial amyloidosis	1
Primary hyperoxaluria	1
Presence of HCC: n	4
Time from OLT to ERCP (wk)
mean ± SD	116 ± 156
Median	45
Range	4-570
Patients with previous endoscopic treatment before Am-FCSEMS, n (%)	8 (57.14)
Procedures before Am-FCSEMS (mean)	2.25
Patients with no previous endoscopic treatment, n (%)	6 (42.86)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; NASH: Nonalcoholic steatohepatitis; HCC: Hepatocellular carcinoma; ERCP: Endoscopic retrograde cholangiopancreatography; Am-FCSEMS: Fully covered self-expandable metal stents with anti-migration flaps.

Table 2 Overall results

Overall results
No. of patients, n	14
Technical success, n (%)	14 (100)
Stricture resolution, n (%)	13 (92.85)
Treatment failure, n (%)	1 (7.14)
Mean ALT before stent (U/L)	144
Mean ALT at the end of follow-up (U/L)	16
Mean total bilirubin before stent (mg/dL)	1. 88
Mean total bilirubin at the end of follow-up (mg/dL)	0. 49
Stricture recurrence, n	0
Stent migration	0
Other complications, n (%)	3 (21.42)
Acute pancreatitis	2 (14.28)
Stent occlusion	1 (7.14)
Mean follow-up after stent removal (d)	411 ± 172

ALT: Alanine aminotransferase.